Companies: 48,874 Total Market Cap: 132455990692658.24

STCube

KOSDAQ-052020
Electronic Parts and Equipment, not elsewhere classified
Rank #17649
Market Cap 273.67 M
Volume 57,287
Price 4.38
Change (%) 0.16%
Country or region South Korea South Korea

STCube's latest marketcap:

273.67 M

As of 05/20/2025, STCube's market capitalization has reached $273.67 M. According to our data, STCube is the 17649th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 273.67 M
Revenue (ttm) 8.06 M
Net Income (ttm) -15,284,305.15
Shares Out 67.93 M
EPS (ttm) -0.31
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 05/14/2025
Market Cap Chart
Data Updated: 05/20/2025

STCube's yearly market capitalization.

STCube has seen its market value grow from ₩309.42 B to ₩383.82 B since 2020, representing a total increase of 24.05% and an annual compound growth rate (CAGR) of 5.04%.
Date Market Cap Change (%)
05/20/2025 ₩383.82 B -33.85%
12/30/2024 ₩580.25 B 4.95%
12/28/2023 ₩552.90 B -13.69%
12/29/2022 ₩640.57 B 141.43%
12/30/2021 ₩265.32 B -14.25%
12/30/2020 ₩309.42 B

Company Profile

About STCube, Inc.

STCube, Inc. is a biopharmaceutical company based in Seoul, South Korea, specializing in the development of innovative medicines. Formerly known as Schem Co., Ltd., the company rebranded to STCube, Inc. in April 2008.

Core Focus Areas

  • Anti-Cancer Immunotherapeutics: Developing treatments targeting various cancers.
  • Anti-Viral Drugs: Researching therapies to combat viral infections.

Platform Technologies

  • In vivo RNAi ICP Target Discovery: Identifies immune checkpoint (ICP) targets.
  • Glycosylation-Specific Antibody Development: Creates antibodies to mask glycosylation sites.
  • ICP Functional Assay Platform: Enables in vivo/in vitro analysis for drug development.

Product Pipeline

  • Preclinical Stage: Anti PD-L1 Ab, Anti PD-1 Ab, and Anti STT-005 (solid tumor).
  • Phase-1 Trial: Anti STT-003 Ab (lung, head, and neck cancer).
  • Small Molecule Inhibitor: STT-011 (pancreatic cancer).
  • Other Candidates: Anti STT-012 Ab (breast/prostate cancer), Anti STT-013 Ab (solid tumor).

Founded: 1989 | Headquarters: Seoul, South Korea

Frequently Asked Questions

As of 05/20/2025, STCube (including the parent company, if applicable) has an estimated market capitalization of $273.67 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

STCube global market capitalization ranking is approximately 17649 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region South Korea
Founded 1989
IPO Date n/a
Employees 17
CEO Hyunjin Jung
Sector
Industry Electronic Parts and Equipment, not elsewhere classified
Address #2201, Korea World Trade Center Trade Tower
Seoul, 06164
South Korea
Website https://www.stcube.com
People Also Watch
TYO-167A
17.02 0.16%
Kuroda Group
6.54 0.16%
KLSE-FCW
0.37 0.16%
BOM-500179
0.26 0.16%